Collegium Pharmaceutical, Inc. (COLL)
Collegium Pharmaceutical, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Collegium Pharmaceutical, Inc. (COLL) is a Drug Manufacturers - Specialty & Generic company based in US with a market capitalization of $1.1B. Revenue grew 23.6% year-over-year and the company generated $327.6M in free cash flow. This page tracks COLL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 357 employees · IPO May 7, 2015
Valuation
Valuation & price
$33.78as of May 17, 2026· -32.2% vs 52w high
21.3
P/E ratio
Latest-FY diluted EPS
3.59
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$1.1B
Market cap
23.6%
Revenue growth (YoY)
59.4%
Gross margin
$327.6M
Free cash flow (USD)
$534M
Net debt
-1.8%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
4
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 30, 2026Filing
Acquisition Completed
- Insider sellMay 20, 2026Filing
Insider Sell $681Freund John Gordon · Director · $681
- Insider sellMay 18, 2026Filing
Insider Sell $143KFreund John Gordon · Director · $142.5K
- Insider sellMay 15, 2026Filing
Insider Sell $162KLurker Nancy · Director · $161.9K
- 8-K eventMay 15, 2026Filing
Annual Meeting Results
- Insider sellMay 13, 2026Filing
Insider Sell $323KBOHLIN GAREN G · Director · $323.5K
- 8-K eventMay 12, 2026Filing
Equity Incentive Plan Established
- 8-K eventMay 7, 2026Filing
Earnings Release
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- 8-K eventApr 7, 2026Filing
Director Nomination and Retirement
Questions
Frequently asked questions
What is Collegium Pharmaceutical, Inc.'s market cap?
Collegium Pharmaceutical, Inc. (COLL) has a market capitalization of $1.1B.
What is COLL's P/E ratio?
COLL trades at a price-to-earnings ratio of 21.3, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is COLL's price-to-book (P/B) ratio?
COLL trades at 3.59 times book value per share.
Are insiders buying COLL stock?
SEC Form 4 filings show no open-market insider buys at Collegium Pharmaceutical, Inc. in the last 90 days (4 sells).
Same arena
Related companies in Drug Manufacturers - Specialty & Generic
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.